Literature DB >> 21773844

Constipation triggered the malignant syndrome in Parkinson's disease.

Emina Ogawa1, Ryuji Sakakibara, Masahiko Kishi, Fuyuki Tateno.   

Abstract

A 69-year-old, chronically constipated patient with Parkinson's disease developed fecal impaction and the malignant syndrome simultaneously, even while the patient was taking anti-parkinsonian drugs as prescribed. Administration of intravenous levodopa and oral Dai-kenchu-tou, an herbal medicine with serotonergic 5-HT3 receptor agonistic property successfully ameliorated his clinical symptoms. Constipation may trigger worsening of Parkinson's disease and occurrence of the malignant syndrome by affecting levodopa absorption. Further, improved bowel motility may prevent worsening of Parkinson's disease and occurrence of the malignant syndrome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21773844     DOI: 10.1007/s10072-011-0710-5

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  9 in total

1.  Dietary herb extract dai-kenchu-to ameliorates constipation in parkinsonian patients (Parkinson's disease and multiple system atrophy).

Authors:  Ryuji Sakakibara; Takeo Odaka; Zhi Lui; Tomoyuki Uchiyama; Kazuya Yamaguchi; Taketo Yamaguchi; Masato Asahina; Tatsuya Yamamoto; Takashi Ito; Takamichi Hattori
Journal:  Mov Disord       Date:  2005-02       Impact factor: 10.338

2.  Akinetic crisis, acute akinesia, neuroleptic malignant-like syndrome, Parkinsonism-hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal.

Authors:  Astrid Thomas; Marco Onofrj
Journal:  Mov Disord       Date:  2005-12       Impact factor: 10.338

3.  Assessment of gastric emptying by radio-nuclide study.

Authors:  A N Supe; S K Mathur; B G Parulkar; S K Patankar; A B Samsi; G H Tilve
Journal:  J Postgrad Med       Date:  1986-10       Impact factor: 1.476

4.  Acute hypernatremia and neuroleptic malignant syndrome in Parkinson disease.

Authors:  L Cao; R H Katz
Journal:  Am J Med Sci       Date:  1999-07       Impact factor: 2.378

5.  Acute akinesia in Parkinson disease.

Authors:  Marco Onofrj; Astrid Thomas
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

6.  Intestinal pseudo-obstruction and neuroleptic malignant syndrome in a chronically constipated parkinsonian patient.

Authors:  J Shimada; R Sakakibara; T Uchiyama; Z Liu; T Yamamoto; T Ito; M Mori; M Asahina; T Hattori
Journal:  Eur J Neurol       Date:  2006-03       Impact factor: 6.089

7.  Gastric myoelectrical differences between Parkinson's disease and multiple system atrophy.

Authors:  Yumi Sakakibara; Masato Asahina; Atsuya Suzuki; Takamichi Hattori
Journal:  Mov Disord       Date:  2009-08-15       Impact factor: 10.338

8.  The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease.

Authors:  W D Neira; V Sanchez; M A Mena; J G de Yebenes
Journal:  Mov Disord       Date:  1995-01       Impact factor: 10.338

Review 9.  Bladder and bowel dysfunction in Parkinson's disease.

Authors:  R Sakakibara; T Uchiyama; T Yamanishi; K Shirai; T Hattori
Journal:  J Neural Transm (Vienna)       Date:  2008-03-10       Impact factor: 3.575

  9 in total
  6 in total

Review 1.  Gastrointestinal dysfunction in movement disorders.

Authors:  Ryuji Sakakibara
Journal:  Neurol Sci       Date:  2021-02-04       Impact factor: 3.307

Review 2.  Parkinsonism-Hyperpyrexia Syndrome and Dyskinesia-Hyperpyrexia Syndrome in Parkinson's Disease: Two Cases and Literature Review.

Authors:  Jian-Yong Wang; Jie-Fan Huang; Shi-Guo Zhu; Shi-Shi Huang; Rong-Pei Liu; Bei-Lei Hu; Jian-Hong Zhu; Xiong Zhang
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

3.  Neuroleptic malignant-like syndrome with a slight elevation of creatine-kinase levels and respiratory failure in a patient with Parkinson's disease.

Authors:  Li Wei; Yinghui Chen
Journal:  Patient Prefer Adherence       Date:  2014-02-27       Impact factor: 2.711

4.  Recurrent Falls in People with Parkinson's Disease without Cognitive Impairment: Focusing on Modifiable Risk Factors.

Authors:  Lorena R S Almeida; Guilherme T Valença; Nádja N Negreiros; Elen B Pinto; Jamary Oliveira-Filho
Journal:  Parkinsons Dis       Date:  2014-11-23

Review 5.  The Human Experience with Intravenous Levodopa.

Authors:  Shan H Siddiqi; Natalia K Abraham; Christopher L Geiger; Morvarid Karimi; Joel S Perlmutter; Kevin J Black
Journal:  Front Pharmacol       Date:  2016-01-06       Impact factor: 5.810

6.  A randomized double-blind placebo-controlled multicenter trial of Bushen Yisui and Ziyin Jiangzhuo formula for constipation in Parkinson disease.

Authors:  Zhaohui Jin; Zhengtang Liu; Lei Kang; Aoran Yang; Hongbo Zhao; XiaoYan Yan; Tianqing Zhang; Lei Gao; Aixian Liu; Boyan Fang
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.